MedTrace Logo

Phase 2 Study - Erdosteine in Patients With CB/COPD

NCT00338507 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2007-12-06

No results posted yet for this study

Summary

This clinical study is designed to explore dose ranging and identify methods to demonstrate the efficacy of Erdosteine in patients with stable Chronic Bronchitis associated with Chronic Obstructive Pulmonary Disease.

Conditions

Interventions

DRUG

Erdosteine

Sponsors & Collaborators

  • Adams Respiratory Therapeutics

    lead INDUSTRY

Principal Investigators

  • Helmut Albrecht, MD · Adams Respiratory Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00338507 on ClinicalTrials.gov